RZLT · Rezolute, Inc. · Documents
$3.93
+0.07 (+1.68%)
At close · Oct 23
Return incl. dividend (before tax)
Market Cap
$373.35M
Shares
96.72M
Volume · Oct 23
547.34K
Avg daily vol (3M)
1.5M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| DEF 14A | Rezolute, Inc. will hold its 2027 Annual Meeting on December 2, 2026 to elect seven directors, ratify Grant Thornton LLP, approve say-on-pay, and increase authorized common stock from 165,000,000 shares to 225,000,000 shares. | 2026-10-21 | 2026-12-02 | |
| 8-K | Rezolute completed enrollment in the Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism, with topline results expected mid-December 2026; earlier, 7 of 8 participants in the study’s first half met the primary responder criterion. | 2026-10-14 | — | |
| PRE 14A | Rezolute’s 2027 Annual Meeting is scheduled for December 2, 2026, with stockholders voting on seven director nominees, Grant Thornton LLP, executive compensation, an authorized-share increase to 225,000,000 shares, and possible adjournment. | 2026-10-07 | 2026-12-02 | |
| 8-K | — | 2026-10-05 | — | |
| 8-K | — | 2026-09-24 | — | |
| 10-K | — | 2026-09-24 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-06-04 | 2025-12-31 | |
| 8-K | — | 2026-06-02 | — | |
| Investor Event Transcript | — | 2026-05-20 | 2025-12-31 | |
| 8-K | — | 2026-05-12 | — | |
| 10-Q | — | 2026-05-12 | 2026-03-31 | |
| 8-K | — | 2026-05-04 | 2026-05-01 | |
| 8-K | — | 2026-03-24 | — | |
| 8-K | — | 2026-02-12 | — | |
| 10-Q | — | 2026-02-12 | 2025-12-31 | |
| 8-K | — | 2026-01-07 | — | |
| S-3ASR | — | 2025-12-05 | — | |
| 8-K | — | 2025-11-21 | 2025-11-19 | |
| 8-K | — | 2025-11-12 | 2025-11-10 | |
| 8-K | — | 2025-11-06 | — | |
| 10-Q | — | 2025-11-06 | 2025-09-30 | |
| 8-K | — | 2025-10-21 | 2025-10-17 | |
| DEF 14A | — | 2025-10-07 | 2025-11-19 | |
| 10-K | — | 2025-09-17 | 2025-06-30 | |
| 8-K | — | 2025-09-17 | — | |
| 8-K | — | 2025-09-02 | — | |
| 8-K | — | 2025-08-20 | 2025-08-18 | |
| 8-K | — | 2025-07-18 | 2025-07-15 | |
| S-3 | — | 2025-07-17 | — | |
| 8-K/A | — | 2025-06-13 | 2025-03-25 | |
| 8-K | — | 2025-06-13 | — | |
| 8-K | — | 2025-05-13 | — | |
| 10-Q | — | 2025-05-13 | 2025-03-31 | |
| 8-K | — | 2025-04-28 | 2025-04-25 | |
| 8-K | — | 2025-04-23 | — | |
| 8-K | — | 2025-04-23 | — | |
| 8-K | — | 2025-03-28 | 2025-03-25 | |
| 10-Q | — | 2025-02-12 | 2024-12-31 | |
| 8-K | — | 2025-02-12 | — | |
| 8-K | — | 2025-02-04 | — | |
| 8-K | — | 2025-01-14 | 2025-01-10 | |
| 8-K | — | 2025-01-07 | — | |
| 8-K | — | 2024-12-10 | 2024-12-05 | |
| 8-K | — | 2024-11-07 | — | |
| 10-Q | — | 2024-11-07 | 2024-09-30 | |
| DEF 14A | — | 2024-10-21 | 2024-12-05 | |
| DEFA14A | — | 2024-10-21 | — | |
| PRE 14A | — | 2024-10-10 | 2024-12-05 | |
| 10-K | — | 2024-09-19 | 2024-06-30 | |
| 8-K | — | 2024-09-19 | — |
Showing 1–50 of 149 filings
Key facts
CIK
1509261
CUSIP
76200L309
13F (30d)
13 filings
13 filers
Visit website
Investor relations